<< Read Full Article
<< Read Full Article
Dendreon Shares Soar on Provenge Data
Dendreon's(DNDN Quote) prostate cancer vaccine Provenge appears to cut the risk of death compared with a placebo, but the interim results were not robust enough to stop the ongoing clinical trial early.
Investors focused on the promising Provenge survival data Monday morning and looked past the disappointment that Dendreon would be unable to seek early approval for the experimental cancer vaccine.
Shares of Dendreon were up 65% to $8.58 in recent trading. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet